## Brajendra K Tripathi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8541693/publications.pdf

Version: 2024-02-01

933447 940533 16 417 10 16 citations g-index h-index papers 16 16 16 878 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nature Communications, 2018, 9, 1960.	12.8	90
2	An Apela RNA-Containing Negative Feedback Loop Regulates p53-Mediated Apoptosis in Embryonic Stem Cells. Cell Stem Cell, 2015, 16, 669-683.	11.1	78
3	CDK5 is a major regulator of the tumor suppressor DLC1. Journal of Cell Biology, 2014, 207, 627-642.	5.2	46
4	A Specific Interaction between Muskelin and the Cyclin-dependent Kinase 5 Activator p39 Promotes Peripheral Localization of Muskelin. Journal of Biological Chemistry, 2005, 280, 21376-21383.	3.4	32
5	Cdk5-Dependent Regulation of Rho Activity, Cytoskeletal Contraction, and Epithelial Cell Migration via Suppression of Src and p190RhoGAP. Molecular and Cellular Biology, 2009, 29, 6488-6499.	2.3	31
6	Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1. Journal of Cell Biology, 2017, 216, 4255-4270.	5.2	28
7	Inactivation of the $\langle i \rangle$ Dlc1 $\langle i \rangle$ Gene Cooperates with Downregulation of $\langle i \rangle$ p15INK4b $\langle i \rangle$ and $\langle i \rangle$ p16Ink4a $\langle i \rangle$ , Leading to Neoplastic Transformation and Poor Prognosis in Human Cancer. Cancer Research, 2012, 72, 5900-5911.	0.9	27
8	The Cdk5 activator P39 specifically links muskelin to myosin II and regulates stress fiber formation and actin organization in lens. Experimental Cell Research, 2015, 330, 186-198.	2.6	15
9	Cancer-Associated Point Mutations in the <i>DLC1</i> Tumor Suppressor and Other <i>Rho-GAPs</i> Occur Frequently and Are Associated with Decreased Function. Cancer Research, 2020, 80, 3568-3579.	0.9	14
10	Cdk5. Cell Adhesion and Migration, 2010, 4, 333-336.	2.7	11
11	SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions. Journal of Cell Biology, 2019, 218, 3060-3076.	5.2	10
12	Distinct functions of Cdk5(Y15) phosphorylation and Cdk5 activity in stress fiber formation and organization. Experimental Cell Research, 2008, 314, 3542-3550.	2.6	9
13	The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo. Molecular Vision, 2008, 14, 542-9.	1.1	9
14	The CDK5 activator, p39, binds specifically to myosin essential light chain. Biochemical and Biophysical Research Communications, 2007, 354, 1034-1039.	2.1	8
15	Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein. Nature Communications, 2021, 12, 6941.	12.8	5
16	DLC1: a tumor suppressor that regulates Rho signaling. Oncotarget, 2017, 8, 27674-27675.	1.8	4